Literature DB >> 9299590

The role of Rel/NF-kappa B proteins in viral oncogenesis and the regulation of viral transcription.

G Mosialos1.   

Abstract

Rel/NF-kappa B is a ubiquitous transcription factor that consists of multiple polypeptide subunits, and is subject to complex regulatory mechanisms that involve protein-protein interactions, phosphorylation, ubiquitination, proteolytic degradation, and nucleocytoplasmic translocation. The sophisticated control of Rel/NF-kappa B activity is not surprising since this transcription factor is involved in a wide array of cellular responses to extracellular cues, associated with growth, development, apoptosis, and pathogen invasion. Thus, it is not unexpected that this versatile cellular homeostatic switch would be affected by a variety of viral pathogens, which have evolved mechanisms to utilize various aspects of Rel/NF-kappa B activity to facilitate their replication, cell survival and possibly evasion of immune responses. This review will cover the molecular mechanisms that are utilized by mammalian oncogenic viruses to affect the activity of Rel/NF-kappa B transcription factors and the role of Rel/NF-kappa B in the regulation of viral gene expression and replication.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9299590     DOI: 10.1006/scbi.1997.0063

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  14 in total

Review 1.  Series introduction: the transcription factor NF-kappaB and human disease.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 2.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

3.  IkappaB kinase-dependent chronic activation of NF-kappaB is necessary for p21(WAF1/Cip1) inhibition of differentiation-induced apoptosis of monocytes.

Authors:  K N Pennington; J A Taylor; G D Bren; C V Paya
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

4.  Biocompatibility of solid-dosage forms of anti-human immunodeficiency virus type 1 microbicides with the human cervicovaginal mucosa modeled ex vivo.

Authors:  Radiana T Trifonova; Jenna-Malia Pasicznyk; Raina N Fichorova
Journal:  Antimicrob Agents Chemother       Date:  2006-10-09       Impact factor: 5.191

5.  Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway.

Authors:  A E Morelli; A T Larregina; R W Ganster; A F Zahorchak; J M Plowey; T Takayama; A J Logar; P D Robbins; L D Falo; A W Thomson
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 6.  NF-kB in development and progression of human cancer.

Authors:  Xavier Dolcet; David Llobet; Judit Pallares; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2005-04-27       Impact factor: 4.064

Review 7.  Nf-kappa B, chemokine gene transcription and tumour growth.

Authors:  Ann Richmond
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

8.  c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.

Authors:  Nathalie Faumont; Stéphanie Durand-Panteix; Martin Schlee; Sebastian Grömminger; Marino Schuhmacher; Michael Hölzel; Gerhard Laux; Reinhard Mailhammer; Andreas Rosenwald; Louis M Staudt; Georg W Bornkamm; Jean Feuillard
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

Review 9.  NF-kappaB and cancer: how intimate is this relationship.

Authors:  Sahdeo Prasad; Jayaraj Ravindran; Bharat B Aggarwal
Journal:  Mol Cell Biochem       Date:  2009-10-08       Impact factor: 3.396

10.  Inhibition of NF-kappaB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver.

Authors:  A Lieber; C Y He; L Meuse; C Himeda; C Wilson; M A Kay
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.